Description
Trilactan Pharmacodynamics
Latanoprost, a prostaglandin F2alpha analogue, is a selective FP (prostaglandin F) receptor agonist and decreases intraocular pressure (IOP) by increasing
outflow of aqueous humor, mainly by the uveoscleral route, as well as through the trabecular meshwork. IOP reduction begins approximately 3-4 hours after
The maximum effect is observed after 8-12 hours; the action lasts for at least 24 hours. It is established that latanoprost has no significant effect on aqueous humor production and on haemato-ophthalmic barrier. When used in therapeutic doses, latanoprost has no significant pharmacological effect on the cardiovascular and respiratory systems.
Indications
Decrease of increased intraocular pressure in adults and children (older than 1 year) with open angle glaucoma or increased ophthalmotonus
Contraindications
Hypersensitivity to latanoprost or other drug components.
Age less than 1 year (efficacy and safety have not been established).
Caution
Aphakia, pseudoaphakia with rupture of the posterior lens capsule; patients with risk factors of macular edema (cases of development of
macular edema, including cystoid edema); inflammatory, neovascular glaucoma (due to insufficient experience with the drug); bronchial asthma;
herpetic keratitis in anamnesis.
Avoid using the drug in patients with an active form of herpetic keratitis and recurrent herpetic keratitis, especially associated with taking prostaglandin F2alpha analogues. The drug should be used with caution in patients with risk factors for iritis/veitis. There are limited data on the use of the drug in patients scheduled for surgical intervention for cataract. In this regard, the drug should be used with caution in this group of patients.
Administration during pregnancy and breast feeding period.
Pregnancy
The safety of using latanoprost during pregnancy in humans has not been established. Latanoprost may have toxic effects on pregnancy, fetus and newborn. Use during pregnancy is contraindicated.
Breastfeeding period
Latanoprost and its metabolites may penetrate into breast milk. Use during breastfeeding is contraindicated. If it is necessary to use the drug
Breastfeeding should be stopped
Fertility
No effect of latanoprost on male and female fertility was found in animal studies.
Dosage and administration regimen
- Dosage regimen in adults (including elderly)
- One drop in the affected eye(s) once a day. Optimal effect is achieved when using in the evening.
- The drug should not be instilled more frequently than once a day, because it has been shown that more frequent administration reduces the hypotensive effect.
- If one dose is missed, treatment is continued according to the usual scheme. As with any eye drops, in order to reduce the possible systemic effect of the drug,
- Immediately after instillation of each drop it is recommended to press the lower lacrimal point located at the inner corner of the eye on the lower eyelid for 1 minute. This procedure should be carried out immediately after instillation.
- Contact lenses should be removed before instillation and inserted not earlier than 15 min after instillation (see also section “Special Precautions”). If other eye drops have to be administered at the same time, their administration should be separated by 5-minute intervals.
- Dosage regimen in children
- Latanoprost is used in children in the same dose as in adults. There are no data on the use of the drug in preterm infants (gestational age < 36 weeks). The data in
- In children < 1 year of age are severely limited.
- Order of Use with Emphasis:
1. Take the stopper and the vial out of the package.
2. open the bottle with the stopper.
3. Fasten the stop to the neck of the vial.
4. Place the stopper on the eyelid so that the dropper is in front of the eyeball, drip the desired amount of drug.
5. Remove the stopper from the neck of the bottle.
6. Close the bottle with the cap.
